Skip to main content

Table 1 Demographic data and core AD biomarker levels for the clinical studya

From: Full-length and C-terminal neurogranin in Alzheimer’s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays

  Control MCI-AD AD
Number (Women/Men) 26 (17/9) 18 (13/5) 23 (17/6)
Age (years) 62 (53–69), P = 0.007c 70 (69–78), P = 0.007b 68 (64–72)
MMSE 27 (25–28) 27 (26–28) 22 (16–24), P < 0.00001b, P = 0.00002c
1–42 (ng/L) 970 (811–1091), P = 0.00002c 558 (377–667), P < 0.00002b 496 (459–568), P < 0.00001b
T-tau (ng/L) 182 (154–207), P < 0.00001c 570 (520–717), P < 0.00001b 618 (527–734), P < 0.00001b
P-tau (ng/L) 35 (30–41), P < 0.00001c 86 (79–104), P < 0.00001b 90 (73–108), P < 0.00001b
  1. aData are given as median (interquartile range) unless otherwise indicated. Statistical differences were determined using non-parametric tests. The demographic data and the core AD biomarkers have partially previously been reported [6]
  2. bCompared with controls
  3. cCompared with MCI-AD